Breakthrough Devices Program: Where’s the value?

To find out more about the FDA’s Breakthrough Devices Program and its potential value for your organization, please join Parexel’s MedTech Regulatory Strategy and Health Advances MedTech consulting leaders, along with medical device innovators who have been through the process, in this webinar-on-demand.

What you will learn:

  1. Motivations for, and expectations associated with being part of the Breakthrough Devices Program 
  2. Challenges and benefits of the program overall, beyond working more closely with the FDA
  3. Experiences throughout the process and implications for development and commercialization timelines
  4. Key lessons learned from those who’ve been through the process 
  5. Considerations for whether and how to pursue breakthrough status

Return to Insights Center

Related Insights

Blog

New FDA draft guidance: Implications for simplifying interchangeability for biosimilars in the US

Jul 16, 2024

Article

Relyvrio Approval: Lessons Learned

Oct 31, 2022

Podcast

RBQM Podcast Series | Episode 3: Staying within the Guardrails: How to Push the Boundaries in a Highly Regulated Industry

Jun 16, 2022

Article

8 things you need to know about eCTDs in China

Jul 1, 2022

Blog

Preparing for the New Era of Hybrid Regulatory Inspections

Jul 11, 2022

Article

EU Orphan Drug Designation – overcoming regulatory challenges

Jul 20, 2022

Video

Cell & Gene Therapies: A Regulatory Update

Jul 22, 2022

Blog

U.S. drug price reform of 2022: What does the Inflation Reduction Act mean for drug manufacturers?

Aug 17, 2022

Article

Q&A Project Optimus: What you need to know

Oct 11, 2022

Article

Five strategies for meeting the requirements of Project Optimus and improving the chances of approval

Nov 10, 2022

Article

New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle

May 10, 2022

Playbook

Are you using real-world evidence?

Feb 1, 2023